Compare ASTH & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTH | BBNX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2025 |
| Metric | ASTH | BBNX |
|---|---|---|
| Price | $25.41 | $31.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $41.33 | $28.55 |
| AVG Volume (30 Days) | 531.7K | ★ 1.0M |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $2,896,452,000.00 | $88,570,000.00 |
| Revenue This Year | $58.46 | $52.13 |
| Revenue Next Year | $25.59 | $36.16 |
| P/E Ratio | $128.58 | ★ N/A |
| Revenue Growth | ★ 68.17 | 67.01 |
| 52 Week Low | $20.12 | $8.89 |
| 52 Week High | $39.97 | $32.71 |
| Indicator | ASTH | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 63.34 |
| Support Level | $21.98 | $28.59 |
| Resistance Level | $25.48 | $32.26 |
| Average True Range (ATR) | 0.99 | 1.67 |
| MACD | 0.57 | 0.06 |
| Stochastic Oscillator | 97.11 | 86.01 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.